By Katie Sorensen, NP-C | Weight Loss NP
Retatrutide weight loss results are getting a lot of attention right now. They’re impressive, and I’m genuinely excited for it to be FDA approved, hopefully fairly soon!
New Phase 3 data show meaningful weight loss in people with obesity, including people with type 2 diabetes. That is worth paying attention to because patients with type 2 diabetes often have a harder time losing weight than patients without diabetes.
But this part is important:
Retatrutide is still investigational. It is not FDA approved. It is not legally available as a prescription weight loss medication. It cannot be legally compounded. And if you see someone selling “retatrutide” online right now, that should raise a red flag.
So yes, the research is exciting.
But this is not the time to abandon a safe, working medical weight loss plan or buy a research peptide online.
Here is what the new retatrutide results actually show.
What is retatrutide?
Retatrutide is an investigational medication being studied by Eli Lilly for obesity, overweight, type 2 diabetes, and other cardiometabolic conditions. Lilly describes retatrutide as an investigational molecule that is still being evaluated in clinical trials and is available only to participants in Lilly clinical trials. Lilly’s patient information on retatrutide
It is often called a “triple G” medication, because it acts on three hormone receptor pathways:
- GIP
- GLP-1
- Glucagon
For comparison, semaglutide acts on GLP-1. Tirzepatide acts on GIP and GLP-1. Retatrutide adds glucagon receptor activity to that picture. Researchers are studying whether that triple-hormone effect may lead to greater weight loss and metabolic improvement.
That does not mean it is automatically better for every patient.
It means it is promising enough to study carefully.
Learn more about our GLP-1 weight loss program.
What did the Phase 3 retatrutide results show?
There are two important pieces of recent Phase 3 data patients may hear about.
First, Lilly announced detailed TRIUMPH-2 results in adults with obesity or overweight and type 2 diabetes. In that study, participants taking retatrutide 12 mg lost an average of 49.6 pounds, or 20.8% of body weight, over 80 weeks. A1C also decreased by up to an average of 1.6%. Lilly TRIUMPH-2 retatrutide announcement
That is a significant result, especially in a type 2 diabetes population.
Second, a Phase 3 trial published in The New England Journal of Medicine studied adults with obesity without diabetes. In that trial, retatrutide 12 mg was associated with an average 25.0% reduction in body weight at 80 weeks, compared with 3.9% with placebo. New England Journal of Medicine retatrutide Phase 3 trial
These results are why retatrutide is making headlines.
But trial results are not the same as FDA approval.
Is retatrutide FDA approved?
No. Retatrutide is not currently FDA approved.
Lilly states that retatrutide is an investigational molecule available only to participants in Lilly clinical trials, where its safety and effectiveness are still being evaluated. Lilly’s patient information on retatrutide
A medication can have exciting clinical trial results and still not be ready for routine prescribing. FDA review looks at the full evidence package, including safety, dosing, manufacturing, labeling, and risk-benefit balance.
Until retatrutide is approved, it should not be marketed to patients. Full stop.
Can retatrutide be compounded?
No.
The FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law. FDA guidance on unapproved GLP-1 drugs
If a website, med spa, online seller, or “research peptide” company claims it can sell compounded retatrutide for human use, patients should be extremely cautious.
That is not the same as a legitimate FDA-approved medication.
It is also not the same as being enrolled in a clinical trial.
Why online “retatrutide” is risky
Patients are understandably interested in the next generation of weight loss medication.
They may see ads for:
- Retatrutide
- “Triple G”
- Research peptides
- Lab-grade peptides
- Not-for-human-use products
- Compounded retatrutide
- “Better than tirzepatide” injections
- Peptides sold through social media or private groups
The problem is that these products may not be what they claim to be.
The FDA has warned about unapproved GLP-1 products, illegal online sales, fraudulent products, dosing errors, and products labeled for “research purposes” or “not for human consumption.” FDA guidance on unapproved GLP-1 drugs
With an investigational medication like retatrutide, the safety concern is even more serious.
Patients do not know:
- Whether the product is actually retatrutide
- Whether the dose is accurate
- Whether it is sterile
- Whether it contains contaminants
- Whether it was manufactured safely
- Whether side effects are being monitored
- Whether it interacts with their medical history
- Whether they are getting appropriate follow-up
That is not medical weight loss.
That is gambling with your health.
Should patients wait for retatrutide?
Some patients are already asking whether they should wait for retatrutide instead of starting semaglutide or tirzepatide.
My answer is usually: probably not.
If your health is being affected by obesity, insulin resistance, prediabetes, type 2 diabetes, sleep apnea, joint pain, fatty liver, blood pressure, cholesterol, or weight-related limitations, waiting indefinitely for a future medication is not the best plan. We have incredibly effective, proven, and safe medications to help you RIGHT NOW. Now is always the best time to improve your health.
We already have FDA-approved options.
For the right patient, semaglutide or tirzepatide may be appropriate now. Other medications may also be considered. Nutrition, strength training, sleep, hormone evaluation, and metabolic support can also start now.
Retatrutide may become an important option in the future.
But your health is happening now.
Should current GLP-1 patients switch?
Right now, patients cannot switch to retatrutide outside a clinical trial because it is not approved.
But even after future approval, the answer will still not be “everyone should switch.”
A good medical weight loss plan considers:
- Your diagnosis
- Your current medication response
- Side effects
- Medical history
- Diabetes or prediabetes status
- Cardiovascular risk
- Kidney and liver history
- Insurance coverage
- Budget
- Medication access
- Muscle preservation
- Nutrition
- Long-term maintenance
If you are doing well on semaglutide or tirzepatide, new retatrutide headlines do not automatically mean your current plan is wrong.
The newest medication is not always the best medication for every patient.
Retatrutide vs tirzepatide: what should patients know?
It is tempting to compare retatrutide and tirzepatide directly.
But we need to be careful.
Retatrutide and tirzepatide have been studied in different trials, populations, doses, and research settings. A headline number from one trial should not be used as a direct comparison against another medication without context.
Tirzepatide is already FDA approved under different brand names for specific uses.
Retatrutide is not.
That makes them very different from a patient-care standpoint.
For now, the most practical comparison is this:
Tirzepatide is an approved medication that can be prescribed when clinically appropriate. Retatrutide is an investigational medication that still needs FDA review before it becomes a routine treatment option.
Why medical supervision is still essential
This is where I get a little opinionated.
The obesity medication space is moving fast. That is exciting.
But fast-moving science creates fast-moving marketing.
Patients are being sold medication, peptides, subscriptions, and promises from every direction.
A safe and appropriate medical weight loss plan should include more than access to a vial.
It should include:
- Medical screening
- Medication selection
- Dose planning
- Side effect management
- Protein targets
- Strength training
- Muscle preservation
- Nutrition that fits real life
- Lab review when appropriate
- Hormone and metabolic context
- Maintenance planning
- Follow-up when things are not working
Medication can be a powerful tool.
But the plan around the medication is what helps keep care safe, realistic, and sustainable.
Read more about medical weight loss and when to see a provider.
Retatrutide, GLP-1 care, and medical weight loss in Denver, Arvada, Colorado, Utah, and Florida
Weight Loss NP provides medically supervised GLP-1 and medical weight loss care for patients in Colorado, Utah, and Florida, with local roots in Denver and Arvada.
We help patients understand options like semaglutide and tirzepatide, while also keeping an eye on emerging treatments like retatrutide.
If you are searching for retatrutide in Denver, Arvada, Colorado, Utah, or Florida, the most important thing to know is this:
Retatrutide is not currently an approved treatment option and it is flat out illegal for companies and people to be offering it to you.
But there are safe, proven, legitimate options for medical weight loss now.
At Weight Loss NP, we help patients avoid the hype and build plans based on medical history, goals, safety, access, and long-term success.
Retatrutide weight loss FAQs
Is retatrutide FDA approved for weight loss?
No. Retatrutide is still investigational and is not FDA approved for weight loss, type 2 diabetes, or any other condition at this time. (Lilly’s patient information on retatrutide)
Can I get compounded retatrutide?
No. FDA states that retatrutide cannot be used in compounding under federal law. (FDA guidance on unapproved GLP-1 drugs)
Patients should be cautious about any clinic, website, or seller claiming to offer compounded retatrutide.
Why is retatrutide called “Triple G”?
Retatrutide is called a “Triple G” medication because it acts on three hormone receptor pathways: GIP, GLP-1, and glucagon.
How much weight did people lose on retatrutide?
In Lilly’s TRIUMPH-2 Phase 3 trial in adults with obesity or overweight and type 2 diabetes, participants taking retatrutide 12 mg lost an average of 49.6 pounds, or 20.8% of body weight, over 80 weeks. (Lilly TRIUMPH-2 announcement)
In a separate Phase 3 trial in adults with obesity without diabetes, retatrutide 12 mg was associated with an average 25.0% body weight reduction at 80 weeks. (New England Journal of Medicine Phase 3 trial)
Is retatrutide better than tirzepatide?
We cannot say that based on headlines alone. Retatrutide and tirzepatide have different approval statuses. They have also been studied in different trials, populations, and doses.
Tirzepatide is FDA approved for certain uses. Retatrutide is still investigational.
Should I wait for retatrutide before starting medical weight loss?
Probably not if your health is being affected now. Retatrutide may become an important option in the future.
However, safe and effective options such as semaglutide, tirzepatide, nutrition support, strength training, and metabolic care are available now for appropriate patients.
Can Weight Loss NP help if I am interested in retatrutide or GLP-1 medications?
Yes. Weight Loss NP provides medically supervised GLP-1 and medical weight loss care in Colorado, Utah, and Florida.
While retatrutide is not currently an approved treatment option, we can help you understand safe, legitimate options that may be available now.
Key takeaway
Retatrutide Phase 3 results are exciting.
In recent studies, retatrutide produced substantial weight loss and improvements in blood sugar measures. It may become an important medication in obesity and metabolic care.
But it is not FDA approved right now. It is not legally available as a routine prescription. It cannot legally be compounded. And online “retatrutide” products should be treated with caution.
If you are interested in GLP-1 or next-generation weight loss medication, please do not chase the newest headline alone.
Work with a medical provider who can help you understand what is available now, what is still investigational, and what plan actually fits your body and your health.
+ show Comments
- Hide Comments
add a comment